Serum cytokeratin 18 as a biomarker for gastric cancer

Abstract

Cytokeratin 18 (CK18) fragments are released into circulation during epithelial cell death. M30 (reflect caspase cleaved CK18 fragment) and M65 (reflect total CK18 fragment) enzyme-linked immunosorbent assay (ELISA) detects circulating CK18 fragments released during caspase-dependent or total cell death, respectively; thus, CK18 has the potential of being a biomarker for epithelial cancers. In the present study, we investigated the serum levels of M30 and M65 in patients with gastric cancer, determined correlation of these levels with clinical features, and evaluated the usefulness of these enzymes as diagnostic and prognostic markers.We enrolled 54 gastric cancer patients and 12 healthy volunteers in this study. We measured the serum levels of M30 and M65 by quantitative ELISA.The levels of M30 and M65 in gastric cancer patients were significantly higher than those in healthy volunteers (P = 0.001, P < 0.001). The enzyme levels were elevated with the progress of gastric cancer. The sensitivity and specificity of M30 as a diagnostic marker were 67.5% and 90.9%, respectively, and those of M65 were 70.1% and 90.9%, respectively. The serum levels of M30 and M65 in patient with early gastric cancer were elevated in 38.1% and 66.7%, respectively. Further, increased serum level of M65 is an independent indicator of poor prognosis (P = 0.036).The serum levels of M30 and M65 may be useful biomarkers for gastric cancer as diagnostic markers that can reflect the extent of cancer. Moreover, M65 levels can be 3 used as a prognostic indicator.

Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study

“…Even with surgical management, the prognosis of gastric cancer is still unsatisfactory, with an estimated 5-year survival rate of 20–25% in China (Hartgrink et al, 2009). Considerable efforts have been made to determine the risk factors for gastric cancer and to identify biomarkers in order to enhance screening and early detection and to better predict the clinical outcomes (Saragoni et al, 2013, Tiberio et al, 2015, Oyama et al, 2013, Hiraki et al, 2011, Lv et al, 2015). In addition to intensified screening for early detection, it is of timely and clinical importance to find novel approaches to improve the prognosis and prolong the survival of patients with gastric cancer.…”

Serum profiles of M30, M65 and interleukin-17 compared with C-reactive protein in patients with mild and severe acute pancreatitis

“…Therefore, these antibodies have a diagnostic potential, reflecting apoptosis and/or necrosis in various situations. Increased levels of caspase‐cleaved CK18 are detected in the serum of cancer patients , septic patients and patients with liver disease . In the present study, apoptosis and necrosis are investigated in patients with acute pancreatitis.…”

MiRNA‐199a‐3p: A potential circulating diagnostic biomarker for early gastric cancer

“…Therefore, much effort has been made to develop preliminary screening tests in easily accessible specimens. Serum cytokeratin 18, hypermethylation of Sox17 gene, S100A9/AAT in gastric fluid, proteomics approach, and serum metabolomics were reported as useful diagnostic biomarkers for gastric cancer . More recently, some studies identified miRNA‐378, miRNA‐451, miRNA‐486, and four up‐regulated GC‐associated miRNAs (miRNA‐17‐5p, miRNA‐21, miRNA‐106a, and miRNA‐106b), which also displayed higher expression levels in GC serum .…”